Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

NCT04283539 is registered in ClinicalTrials.gov with National Jewish Health as lead sponsor.

NCT NCT04283539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04283539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
Lead sponsor
National Jewish Health
Phase
Observational
Overall status
Completed
Start date
September 23, 2020
Completion date
February 28, 2026
Enrollment
255 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, immunotherapy, patients with solid tumors receiving immunotherapy with an ici will be randomized to participate in an sdoh and side effects navigation program vs. control, skin disease